Tabelecleucel – VJRegenMed

Remaining barriers in commercializing advanced therapies

Simon Ng — Mon, 29 Nov 2021 11:36:57 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, addresses issues relating to the commercialization of cell and gene therapies. Major challenges remain in terms of logistics and delivery. Off-the-shelf allogeneic therapies can be given to patients quicker than autologous therapies, as in the case of tabelecleucel, a novel CAR-T cell therapy which can be delivered to patients in three days. He additionally highlights reimbursement issues for these one-off treatments. This interview took place at Meeting on the Mesa 2021.

The current landscape of allogeneic CAR T-cell therapies

Simon Ng — Thu, 25 Nov 2021 18:05:19 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, provides an overview of allogeneic chimeric antigen receptor (CAR) T-cell therapies in development. He describes ATA3219, a novel anti-CD19 CAR-T cell therapy developed for B-cell malignancies, as well as ATA2271, a mesothelin-targeted CAR-T immunotherapy for solid tumors. Tabelecleucel is an additional CAR-T cell therapy that treats Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. This interview took place at Meeting on the Mesa 2021.

Tabelecleucel in EBV-associated PTLD

admin_vjr_user — Wed, 14 Apr 2021 16:52:02 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the Phase III MATCH (NCT03392142) and ALLELE (NCT03394365) clinical trials investigating the efficacy and safety of tabelecleucel, an allogeneic EBV-specific T cell therapy, for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) following hematopoietic cell or solid organ transplantation. Results have demonstrated an objective response rate of 50% and a two-year overall survival rate of 80%, which is promising given the median life expectancy in this patient group following first-line therapy is 2-3 months. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Accelerating commercialization in advanced therapies

admin_vjr_user — Sat, 10 Apr 2021 10:57:58 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes a panel discussion that took place at the Cell & Gene Meeting on the Mediterranean 2021 virtual conference, in which leading experts discussed how the field can accelerate the commercialisation of cell and gene therapies. He highlights challenges associated with the regulation of these innovative therapies and proposes that regulatory agencies need to work closely with the industry in order to establish the critical criteria required to demonstrate the efficacy and safety of cell and gene therapies. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.